Revlimid is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat mantle cell lymphoma and multiple myeloma. Revlimid is often combined with other drugs such as a corticosteroid or Velcade (bortezomib). Revlimid is also known by its drug name, lenalidomide.
Revlimid is an immunomodulator – a drug that modulates the immune system. Revlimid is believed to work by preventing cellular proliferation, inducing cellular death, and upregulating the immune system.
How do I take it?
Revlimid is taken orally on specific days in a 28-day cycle.
Revlimid comes in the form of a capsule.
The FDA-approved label for Revlimid lists common side effects including insomnia, dizziness, fever, fatigue, cough, rash, weakness, cold or flu symptoms, bronchitis, trouble breathing, back pain, muscle cramps, tremors, nausea, diarrhea, constipation, abdominal pain, low white blood cell counts, and swelling in the extremities.
Rare but serious side effects listed for Revlimid include severe fetal harm in pregnant women, liver failure, severe skin reactions, and increased risk for heart attack, stroke, dangerous blood clots, and other types of cancer.
Individuals diagnosed with chronic lymphocytic leukemia (CLL) should not take Revlimid due to increased risk for severe and fatal cardiac side effects.
For more details about this treatment, visit:
Revlimid — Celgene
Immunotherapy for Non-Hodgkin Lymphoma — American Cancer Society
Drug Therapy for Multiple Myeloma — American Cancer Society